Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice

Hepatology Research

Volumn 44, Issue 8, 2014, Pages 920-934

  Sawada, Koji ^a   Ohtake, Takaaki ^a   Hasebe, Takumu ^a   Abe, Masami ^a   Tanaka, Hiroki ^a   Ikuta, Katsuya ^a   Suzuki, Yasuaki ^c   Fujiya, Mikihiro ^a   Hasebe, Chitomi ^b   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^c Nayoro City General Hospital   (Japan)

Author keywords

Fatty acids; Gut liver axis; Non alcoholic fatty liver disease; Pro inflammatory state; Toll like receptor

Indexed keywords

FATTY ACID; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; MESSENGER RNA; PALMITIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL OVERGROWTH; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID BLOOD LEVEL; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INFLAMMATORY CELL; INTESTINE FLORA; KUPFFER CELL; LIPID DIET; LIVER CELL; MACROPHAGE; MALE; MORBID OBESITY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; UPREGULATION;

EID: 84904742806     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12199     Document Type: Article

References (35)

1. Ludwig J, Viggiano TR, McGill DB, Brewer NS. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hithero unnamed disease. Mayo Clin Proc 1980; 55: 482-488.
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
3. Day CP, James OF. Steatohepatitis: a role of two "hit"? Gastroenterology 1998; 114: 842-845.
4. Marra F, Bertolani C. Adipokines in liver disease. Hepatology 2009; 50: 957-962.
5. George DK, Goldwurm S, MacDonald GA etal. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1988; 114: 311-318.
6. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptor 2 and 4. Alcohol Clin Exp Res 2005; 29 (11 Suppl): 140S-145.
7. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Gastroenterology 2008; 48: 322-335.
8. Takeda K, Akira S. TLR signaling pathway. Semin Immunol 2004; 16: 3-9.
9. Gustot T, Lemmers A, Moreno C etal. Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43: 989-1000.
10. Rivera CA, Adegvoyage P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579.
11. Imajo K, Fujita K, Yoneda M etal. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin mediated signaling. Cell Metab 2012; 16: 44-54.
12. Miura K, Kodama Y, Inokuchi S etal. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 2010; 139: 323-334.
13. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
14. Shanab AA, Scully P, Crosbie O etal. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-1534.
15. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
16. Cani PD, Bibiloni R, Knauf C etal. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high fat diet induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
17. Bajzer M, Seeley RJ. Obesity and gut flora. Nature 2006; 444: 1009-1010.
18. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould EE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299: G440-448.
19. Vijay-Kumar M, Aitken JD, Carvalho A etal. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.
20. Santaolalla R, Fukata M, Abreu M. Innate immunity in the small intestine. Curr Opin Gastroenterol 2011; 27: 125-131.
21. Lodes MJ, Cong Y, Elson CO etal. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296-1306.
22. Munthe-Kaas AC, Berq T, Seqlen PO, Seljelid R. Mass isolation and culture of rat Kupffer cells. J Exp Med 1975; 141: 1-10.
23. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal 2008; 20: 269-276.
24. Seki E, Minicis SD, Osterreicher CH etal. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
25. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211.
26. Sabate JM, Jouet P, Harnois F etal. High prevalence of small intestinal bacterial overgrowth with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18: 371-377.
27. Pillotto A, Franceschi M, Del Favero G, Fabrello R, Di Mario F, Valerio G. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Aging (Milano) 1995; 7: 234-237.
28. Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A, Sanders DS. Small bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? Gerontology 2005; 51: 396-401.
29. Soza A, Riquelme A, Gonzalez R etal. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 1136-1140.
30. Bertola A, Bonnafous S, Anty R etal. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS ONE 2010; 5: e13577.
31. Rivera CA, Gaskin LT, Allman M etal. Toll-like receptor 2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol 2010; 10: 52.
32. Backhed F, Ding H, Wang T etal. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-15723.
33. Prakash S, Rodes L, Coussa-Charley M, Duchesneau CT. Gut mictobiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011; 5: 71-86.
34. Lee JY, Plakidas A, Lee WH etal. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3polyunsaturated fatty acids. J Lipid Res 2003; 44: 909-916.
35. Lee JY, Gao Z, Youn HS etal. Reciprocal modulation of Toll-like recptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278: 37041-37051.